TRETINOIN MICROSPHERE

Clinical safety rating: avoid

No significant drug interactions Highly teratogenic and can cause severe skin irritation.

How it works

Tretinoin microsphere is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ), modulating gene expression involved in cell proliferation, differentiation, and inflammation. It normalizes follicular keratinization, reduces microcomedone formation, and increases epidermal turnover.

What the body does with it

Metabolism	Tretinoin is primarily metabolized by cytochrome P450 enzymes (CYP2C8, CYP2C9, CYP2B6, CYP3A4) to 4-hydroxy-tretinoin, 4-oxo-tretinoin, and other metabolites. It is also isomerized to isotretinoin and 13-cis-retinoic acid.
Excretion	Primarily hepatic metabolism via CYP450 isoforms to polar metabolites; renal excretion accounts for <1% unchanged; biliary/fecal elimination of metabolites is significant (approximately 30-60%).
Half-life	Terminal elimination half-life approximately 0.5–2 hours in terminal phase; longer terminal phase (10–20 hours) observed for 13-cis-retinoic acid metabolite.
Protein binding	>95% bound to plasma proteins, primarily albumin.
Volume of Distribution	~0.5–0.8 L/kg (IV data from tretinoin); reflects distribution into total body water and some tissue binding.
Bioavailability	Topical: Minimal systemic absorption (<5% of applied dose); oral tretinoin absorption is variable (approximately 50-70% with food).
Onset of Action	Topical: Improvement in acne lesions typically seen within 2–4 weeks of regular use.
Duration of Action	Topical: Effects persist for several weeks after discontinuation; continued improvement may be observed up to 12 weeks.

Classification & Brands

Dosing & administration

Apply a pea-sized amount (approximately 0.5 g) topically once daily at bedtime to dry skin.

Dosage form	GEL
Renal impairment	No dose adjustment required for renal impairment.
Liver impairment	No formal guidelines; use with caution in severe hepatic impairment due to potential accumulation.
Pediatric use	Not recommended for use in pediatric patients below 12 years of age; safety and efficacy not established.
Geriatric use	No specific dose adjustment; apply as in adults, but monitor for increased skin irritation due to thinner skin.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Highly teratogenic and can cause severe skin irritation.

FDA category	Contraindicated
Breastfeeding	No data on excretion in human milk. Tretinoin is naturally present in milk at low levels. After topical application, systemic absorption is minimal, so levels in milk are expected to be negligible. M/P ratio not established. Caution is advised; use only if clearly needed.
Teratogenic Risk	Tretinoin microsphere is a topical retinoid, Pregnancy Category C. Systemic absorption is minimal (<2% of applied dose). First trimester: In animal studies with oral tretinoin, fetal abnormalities (CNS, cardiovascular) occurred. Topical use has limited human data but risk is considered low due to low absorption. Second and third trimesters: Similar considerations; avoid use unless clearly needed. Contraindicated in pregnant women due to potential risk, though absolute risk from topical use is very low.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Common Effects	Erythema skin redness Skin irritation Dry skin Dry lips Pale red skin Increased sensitivity to light
Serious Effects

Absolute Contraindications

["Hypersensitivity to tretinoin or any formulation components","Pregnancy (Category C due to potential teratogenicity; consider alternative therapy)"]

Clinical Precautions

Precautions

["Increased sensitivity to sunlight; use sun protection","Possible severe skin irritation (e.g., erythema, peeling, burning); discontinue if severe","Avoid excessive exposure to wind or cold","Not for use on eczematous or sunburned skin","Risk of temporary worsening of acne during initial treatment"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRETINOIN MICROSPHERE

Clinical safety rating: avoid

No significant drug interactions Highly teratogenic and can cause severe skin irritation.

How it works

What the body does with it

Metabolism	Tretinoin is primarily metabolized by cytochrome P450 enzymes (CYP2C8, CYP2C9, CYP2B6, CYP3A4) to 4-hydroxy-tretinoin, 4-oxo-tretinoin, and other metabolites. It is also isomerized to isotretinoin and 13-cis-retinoic acid.
Excretion	Primarily hepatic metabolism via CYP450 isoforms to polar metabolites; renal excretion accounts for <1% unchanged; biliary/fecal elimination of metabolites is significant (approximately 30-60%).
Half-life	Terminal elimination half-life approximately 0.5–2 hours in terminal phase; longer terminal phase (10–20 hours) observed for 13-cis-retinoic acid metabolite.
Protein binding	>95% bound to plasma proteins, primarily albumin.
Volume of Distribution	~0.5–0.8 L/kg (IV data from tretinoin); reflects distribution into total body water and some tissue binding.
Bioavailability	Topical: Minimal systemic absorption (<5% of applied dose); oral tretinoin absorption is variable (approximately 50-70% with food).
Onset of Action	Topical: Improvement in acne lesions typically seen within 2–4 weeks of regular use.
Duration of Action	Topical: Effects persist for several weeks after discontinuation; continued improvement may be observed up to 12 weeks.

Classification & Brands

Dosing & administration

Apply a pea-sized amount (approximately 0.5 g) topically once daily at bedtime to dry skin.

Dosage form	GEL
Renal impairment	No dose adjustment required for renal impairment.
Liver impairment	No formal guidelines; use with caution in severe hepatic impairment due to potential accumulation.
Pediatric use	Not recommended for use in pediatric patients below 12 years of age; safety and efficacy not established.
Geriatric use	No specific dose adjustment; apply as in adults, but monitor for increased skin irritation due to thinner skin.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Highly teratogenic and can cause severe skin irritation.

FDA category	Contraindicated
Breastfeeding	No data on excretion in human milk. Tretinoin is naturally present in milk at low levels. After topical application, systemic absorption is minimal, so levels in milk are expected to be negligible. M/P ratio not established. Caution is advised; use only if clearly needed.
Teratogenic Risk	Tretinoin microsphere is a topical retinoid, Pregnancy Category C. Systemic absorption is minimal (<2% of applied dose). First trimester: In animal studies with oral tretinoin, fetal abnormalities (CNS, cardiovascular) occurred. Topical use has limited human data but risk is considered low due to low absorption. Second and third trimesters: Similar considerations; avoid use unless clearly needed. Contraindicated in pregnant women due to potential risk, though absolute risk from topical use is very low.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Common Effects	Erythema skin redness Skin irritation Dry skin Dry lips Pale red skin Increased sensitivity to light
Serious Effects

Absolute Contraindications

["Hypersensitivity to tretinoin or any formulation components","Pregnancy (Category C due to potential teratogenicity; consider alternative therapy)"]